LASERS IN DENTAL TREATMENT WITHOUT NEEDLES AND DRILLS
Dr Omar Zuaiter
Co-Founder & Chief Executive Officer, Dentroid
Alaa Habeb
Co-Founder & Chief Technology Officer, Dentroid
Professor Laurence Walsh
Chief Dental Officer, Dentroid &
Emeritus Professor, School of Dentistry, University of Queensland &
Adjunct Professor, Griffith University, Queensland
Professor Heiko Spallek
Member Scientific Advisory Committee, Dentroid &
Head of School and Dean of The University of Sydney School of Dentistry
BENCH SIDE STORY CASE STUDY
Filmed in Brisbane, Canberra & Sydney | December 2024
In 2017, Dr. Omar Zuaiter and Alaa Habeb launched Dentroid, a dental technology startup with a mission to make dentistry a kinder and friendlier experience for patients and dentists using photonics (using laser technology) and robotics, as alternatives to needles, drills and sprays. The vision for the startup is to have dentistry adopt laser technology, addressing the root causes of dental pain & anxiety, and create a pain-free dental experience.
Dentroid is pioneering the adoption of femtosecond lasers in dentistry which will be their first surgical application outside eye surgery. Unlike conventional dental lasers or rotary instruments, femtosecond lasers have a very unique ability to precisely cut through the most resistant materials without requiring cooling or causing thermal damage. This “cold cutting” creates convenience for the patient, clearer vision for the practitioner and a cleaner environment in the office without microbes laden droplets.
A key distinctive feature of femtosecond laser in “cold cutting” is that it leaves the underlying tissues unharmed with the aim of supporting faster healing with less postoperative complications.
Dentroid envisages femtosecond lasers, combined with their patented miniaturised robotic technology will change the way dental tissues and restorative materials are prepared, processed and bonded not only in clinics but also in dental labs.
To support this mission, Dentroid has assembled a multidisciplinary team of world-renowned experts in dentistry and medicine, engineering, robotics, physics, medical sciences and AI informatics together with commercialisation and growth minds who helped scale startups grow to much larger organisations.
In this Bench Side Story Case Study release, we spoke with some of the key people involved in Dentroid mission and commercialisation journey.
FORWARD LOOKING STATEMENTS
This case study may contain projections and forward-looking statements that involve risks and uncertainties, including statements regarding the potential benefits and success of the drug or therapeutic. Actual results could differ materially from those anticipated in these forward-looking statements due to various factors, including but not limited to the risks and uncertainties associated with drug or device development and regulatory approval processes.
Viewers are advised content is for awareness and entertainment purposes only.
-
The world of AI avatars in dementia care
Dementia care is one of the critical issues facing the aged care industry. About 500,000 Australians currently live with the brain disorder condition, and this is tipped to rise to 1.1 million in a generation.
How to effectively provide quality care for people living with dementia was a key element of the royal commission into aged care, which found the complex care required was an ongoing challenge for the industry.
-
Reflecting on a pivotal year for pharmacy
Dr. Kate Wang, a Senior Lecturer in Pharmacy at RMIT University and Adjunct Senior Lecturer, University of Western Australia, has over a decade of experience in both hospital and community pharmacy settings.
Dr Wang spoke to Australian Health Journal on some of the key topics in 2024 that have been pivotal as a pharmacist, academic and researcher for the pharmacy profession.
-
Roadmapping next phase of Australia’s vaccine success
Trust, collaboration and a stronger vaccine ecosystem were the focus of the second Australian Vaccine Value Chain Conference, held in Sydney, September 2026 and hosted by life science consultancy Biointelect. More than 200 leaders from government, industry, academia, research, investment and the immunisation community attended, joined by international representatives including the International Vaccine Institute and the Coalition for Epidemic Preparedness Innovations.
